MGF
Mechano Growth Factor
Non-pegylated MGF is a separate entry from PEG-MGF, but it lands in an equally weak compounding position under the FDA's current framework.
Current status
Restricted
Muscle and recovery-related interest, with current federal compounding constraints still in play.
FDA category
Category 3
Can pharmacies compound this?
No
Reclassification expected?
Unclear
Current federal signals point to an inadequately supported nomination rather than a near-term return to mainstream compounding.
Primary Use
Muscle and recovery-related interest
Regulatory Timeline
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Sep 27, 2024
Current status signal recorded: Placed by FDA in Category 3 because the nomination lacked adequate support..
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Get notified...
Get notified when MGF status changes
State-specific notes
Ohio
Sports-performance peptides remain hard to source compliantly.